All News

RheumNow Podcast square

Maui Potpourri (2.13.2026)

Jack Cush, MD

Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.

Read Article
Haque and Goodman

Obesity, Surgery, and Optimizing Patient Care

Eric Dein, MD

Rheumatologic care involves multidisciplinary approaches and collaboration with specialties to treat complex, systemic diseases. While many Pods at RheumNow Live are disease specific, the Pod II focused on Advancing Practice on important and emerging areas affecting rheumatologic patients. This session focused on two major areas of need: obesity and peri-operative management.

Read Article
Cockerell

Vasculitis

Richard Conway, MBBChBAO, PhD

Sunday’s vasculitis session at RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field: rheumatologist Dr. Mike Putman and dermatopathologist Dr. Clay Cockerell.

Read Article
doctor,black,power,up,optimist

We are Doctors, Not Providers!

Jack Cush, MD

With apologies to Shakespeare, names are important. In health care, they can have ethical significance. The American College of Physicians has published a new ethics/position policy paper proclaiming that the term ‘provider’ should not be used to describe physicians, and using the blanket term undermines physicians’ ethical responsibility, clinical integrity, and professionalism.

Read Article
Sparks RNL26

Advances in RA-ILD

Richard Conway, MBBChBAO, PhD

Dr. Jeffrey Sparks gave a state of the art update on Advances in RA-ILD, many of which he and his group have played a big part in, on Saturday at RNL26. 

Read Article
RheumNow Podcast square

ANA Pollution (2.06.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

Read Article
RNL 26 Report: Spondyloarthritis Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, about lectures presented during the "Staying Ahead of Spondyloarthritis" session. https://t.co/UjvauWoga5 https://t.co/Zv8dmUuVyD

Links:

Dr. John Cush RheumNow ( View Tweet)
The hx and timeline of GLP1a development. @RWCSmtg #RWCS26 https://t.co/7tPgcRy4Ze
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD #RNL26 Placebo in Rheumatology - STEP talk Kerschbaumer What plays role in PBO? Treatment adherence effect w better background therapy - may appear to be PBO Impact in globalization of recruitment patterns, affects background PBO Education of pts bridges gap

Dr. John Cush RheumNow ( View Tweet)

RT @richardPAconway Who to screen for RA-ILD is a tricky one. It is not feasible to screen everyone. This is from ACR/Chest 2023 ILD guidelines and is based on identified risk factors. #RNL26 https://t.co/NtAWYCVclJ
Dr. John Cush RheumNow ( View Tweet)
Vasculitis Sunday’s vasculitis session at RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field. https://t.co/ueg3yJDMu4 https://t.co/8uiI9A5G8x

Links:

Dr. John Cush RheumNow ( View Tweet)
We are Doctors, Not Providers! With apologies to Shakespeare, names are important. In health care, they can have ethical significance. The American College of Physicians (ACP) is concerned about the use of the term provider to describe physicians. https://t.co/Vf6Wx0w28d https://t.co/RXTTFq34Rj

Links:

Dr. John Cush RheumNow ( View Tweet)
Staying Ahead of Spondyloarthritis The diagnosis and treatment of spondyloarthritis can present challenging clinical scenarios for rheumatologists. At RheumNow Live, Pod IV focused on "Staying Ahead of Spondyloarthritis." https://t.co/hZeqYC7wi3 https://t.co/2eKEueAukY

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheum Cases & Guidelines https://t.co/0zI2KRuwxa https://t.co/TBw12LFh6i

Links:

Dr. John Cush RheumNow ( View Tweet)
ANA Pollution (2.06.2026 Dr. Jack Cush reviews the news, journal articles, and regulatory news from this past week on RheumNow. https://t.co/cfEjEr36Tb https://t.co/OJbE6P3k6p

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/TCsDfeQjZC
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinmd Mortality risk in RA #RNL26 Myasoedova Most common mortality: 1.5-1.6x increase risk CVD 2-3x increase risk ILD +ACPA increases risk in both https://t.co/Luwyy6UFg6
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinmd Mortality risk in RA #RNL26 Myasoedova Premature deaths in up to 1/4 of pts Decline in mortality in RA after year 2000 Full siblings of RA also high mortality (shared genetic or environ factors affect risk?) Risks: Seropositivity, esp ACPA, CRP, extra-artic https://t.co/ytm6odmtgR
Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Recent Government Funding The American College of Rheumatology (ACR) praised the recent Congressional CY 26 funding package, highlighting its provisions to extend Medicare telehealth payment flexibilities, enhance transparency in pharmacy benefit management, and https://t.co/gr3X7RRGLN
Dr. John Cush RheumNow ( View Tweet)
REcently published SMILE study looked at the potential of HCQ (vs PBO) to prevent SLE in at risk people. Had to be ANA+ and 1-2 SLICC criteria at entry. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/s4Mzoec5ga
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×